Targets › ACE
18 programs from 17 companies in 18 trials: 8 Phase 4, 5 Phase 3, 5 Phase 2; Cardiovascular, Immunology, Oncology; next expected readout Dec 2026.
Dipeptidyl carboxypeptidase that removes dipeptides from the C-terminus of a variety of circulating hormones, such as angiotensin I, bradykinin or enkephalins, thereby playing a key role in the regulation of blood pressure, electrolyte homeostasis or synaptic plasticity. Composed of two similar catalytic domains, each possessing a functional active site, with different selectivity for substrates. (UniProt, P12821)
Open in Phaseline: the race on ACE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Martin Huelsmann | Enalapril Angiotensin-converting enzyme inhibitor | ACE | Phase 4 | Heart Diseases | Dec 2026 |
| Cedars-Sinai Medical Center | Lisinopril Angiotensin-converting enzyme inhibitor | ACE | Phase 4 | Coronary Artery Disease | Apr 2027 |
| University of Nebraska | Ramipril Angiotensin-converting enzyme inhibitor | ACE | Phase 4 | Peripheral Arterial Disease | Jun 2027 |
| Vastra Gotaland Region | Ramipril Angiotensin-converting enzyme inhibitor | ACE | Phase 4 | Myocardial Infarct | Dec 2027 |
| Nebraska Methodist Health System | Enalapril Angiotensin-converting enzyme inhibitor | ACE | Phase 4 | Hypertension in Pregnancy | Jul 2028 |
| National Heart Centre Singapore | Renin-angiotensin-aldosterone system inhibitors (ACE inhibitors, Angiotensin II ACE inhibition and angiotensin II receptor antagonism | ACE, AGTR1 | Phase 4 | Diabetes Mellitus | Jun 2034 |
| Evi Liliek Wulandari | Ramipril Angiotensin-converting enzyme inhibitor | ACE | Phase 4 | Chronic Kidney Disease | – |
| Fundación EPIC | Ramipril Angiotensin-converting enzyme inhibitor | ACE | Phase 4 | Coronary Artery Disease | – |
| Women and Infants Hospital of Rhode Island | Enalapril Angiotensin-converting enzyme inhibitor | ACE | Phase 3 | Preeclampsia | Oct 2027 |
| Sherief Abd-Elsalam | Ramipril Angiotensin-converting enzyme inhibitor | ACE | Phase 3 | Liver Fibroses | Nov 2027 |
| Northern California Institute of Research and Education | Polycap Fixed-dose combination: aspirin (antiplatelet), simvastatin (HMG-CoA reductase inhibitor), | HMGCR, ACE | Phase 3 | Stroke | Jan 2029 |
| Ain Shams University | Captopril Angiotensin-converting enzyme inhibitor | ACE | Phase 3 | Cardiotoxicity | – |
| HaEmek Medical Center, Israel | Ramipril Angiotensin-converting enzyme inhibitor | ACE | Phase 3 | Persistent Developmental Stuttering | – |
| UNC Lineberger Comprehensive Cancer Center | Lisinopril Angiotensin-converting enzyme inhibitor | ACE | Phase 2 | Chest Wall Tumor | Feb 2029 |
| Oslo University Hospital | Enalapril Angiotensin-converting enzyme inhibitor | ACE | Phase 2 | Venous Malformation | Dec 2029 |
| Northwell Health | Benazepril ACE inhibitor | ACE | Phase 2 | Systemic Lupus Erythematosus | – |
| Northwell Health | Lisinopril Angiotensin-converting enzyme inhibitor | ACE | Phase 2 | Systemic Lupus Erythematosus | – |
| Northwestern University | Lisinopril Angiotensin-converting enzyme inhibitor | ACE | Phase 2 | Hepatocellular Carcinoma | – |
Coronary Artery Disease (2) Systemic Lupus Erythematosus (2) Chronic Kidney Disease (1) Persistent Developmental Stuttering (1) Cardiotoxicity (1) Stroke (1) Venous Malformation (1) Preeclampsia (1) Heart Diseases (1) Myocardial Infarct (1) Hypertension in Pregnancy (1) Peripheral Arterial Disease (1)
small molecule (17), mixed (1)
Northwell Health (2) Evi Liliek Wulandari (1) Cedars-Sinai Medical Center (1) HaEmek Medical Center, Israel (1) Ain Shams University (1) Northern California Institute of Research and Education (1) Oslo University Hospital (1) Women and Infants Hospital of Rhode Island (1) Martin Huelsmann (1) Vastra Gotaland Region (1) Nebraska Methodist Health System (1) University of Nebraska (1) Sherief Abd-Elsalam (1) National Heart Centre Singapore (1) UNC Lineberger Comprehensive Cancer Center (1) Northwestern University (1) Fundación EPIC (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.